ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

J. Armstrong, Andrew; Z. Szmulewitz, Russell; P. Petrylak, Daniel; M. Holzbeierlein, Jeffrey; Villers, Arnauld; Azad, Arun; Alcaraz, Antonio; Yа. Alekseev, B.; Iguchi, Taro; D. Shore, Neal; Rosbrook, Brad; Sugg, Jennifer; Baron, Benoît; Chen, Lucy; Stenzl, Arnulf

doi:10.1200/jco.19.00799

Public

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Published in Journal of Clinical Oncology • Jul 22, 2019

Authors:

Andrew J. Armstrong

Russell Z. Szmulewitz

Daniel P. Petrylak

Abstract

PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS ARCHES (Clinic...

Subject

Enzalutamide

Medicine

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!